Kanters TA, et al. - Authors ascertained the cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria (CSU) relative to standard of care (SoC; up to 4 times the daily dose of H1-antihistamines) in the Netherlands from a societal perspective. Findings suggested cost-effectiveness of Omalizumab vs SoC. In order to establish omalizumab as third-line therapy in the Dutch treatment guidelines for CSU, the outcomes of this study were used. An important role in the value of the incremental cost-effectiveness ratio (ICER) was played by the productivity costs; discarding productivity costs resulted in an ICER of €85,310 per QALY.